[go: up one dir, main page]

MX2010003913A - Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson. - Google Patents

Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson.

Info

Publication number
MX2010003913A
MX2010003913A MX2010003913A MX2010003913A MX2010003913A MX 2010003913 A MX2010003913 A MX 2010003913A MX 2010003913 A MX2010003913 A MX 2010003913A MX 2010003913 A MX2010003913 A MX 2010003913A MX 2010003913 A MX2010003913 A MX 2010003913A
Authority
MX
Mexico
Prior art keywords
organic compounds
modulator
parkinson
progression
disease
Prior art date
Application number
MX2010003913A
Other languages
English (en)
Inventor
Fabrizio Gasparini
Baltazar Gomez-Mancilla
Daniel Umbricht
Th R Se Di Paolo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010003913A publication Critical patent/MX2010003913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

La invenci?n se refiere al uso de un modulador de mGluR, por ejemplo, un modulador de mGluR5 para el tratamiento, prevenci?n o retraso de la progresi?n de la Enfermedad de Parkinson y/o trastornos asociados.
MX2010003913A 2007-10-12 2008-10-09 Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson. MX2010003913A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97948607P 2007-10-12 2007-10-12
US5033308P 2008-05-05 2008-05-05
PCT/EP2008/063544 WO2009047296A2 (en) 2007-10-12 2008-10-09 Metabotropic glutamate receptor modulators for the treatment op parkinson's disease

Publications (1)

Publication Number Publication Date
MX2010003913A true MX2010003913A (es) 2010-04-27

Family

ID=40348021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003913A MX2010003913A (es) 2007-10-12 2008-10-09 Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson.

Country Status (19)

Country Link
US (2) US20100249136A1 (es)
EP (1) EP2211859B1 (es)
JP (2) JP5743545B2 (es)
KR (1) KR101572280B1 (es)
CN (1) CN101854935A (es)
AU (1) AU2008309621A1 (es)
BR (1) BRPI0818560A2 (es)
CA (1) CA2701853A1 (es)
CL (1) CL2008003006A1 (es)
IL (1) IL204954A0 (es)
MA (1) MA31798B1 (es)
MX (1) MX2010003913A (es)
NZ (1) NZ584856A (es)
RU (1) RU2508107C2 (es)
SG (1) SG185293A1 (es)
TN (1) TN2010000155A1 (es)
TW (1) TW200924745A (es)
WO (1) WO2009047296A2 (es)
ZA (1) ZA201002423B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703809B2 (en) 2008-06-30 2014-04-22 Novartis Ag Combination products
NZ590753A (en) * 2008-08-12 2012-06-29 Novartis Ag Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof
WO2011035186A1 (en) * 2009-09-17 2011-03-24 Vanderbilt University Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
JP2014515008A (ja) * 2011-03-03 2014-06-26 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
GB201204962D0 (en) 2012-03-21 2012-05-02 Addex Pharmaceuticals Sa Pharmaceutical combination products for parkinsons disease
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
KR101749675B1 (ko) * 2015-07-20 2017-06-26 동국대학교 산학협력단 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
CA2469821C (en) * 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
AU2003267087A1 (en) * 2002-09-13 2004-04-30 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
EP1596808A4 (en) * 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
EP1715867A4 (en) * 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
MX2007010414A (es) * 2005-03-04 2007-09-25 Hoffmann La Roche Derivados de piridin-2-carboxamida como antagonistas de mglur5.
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
KR20080076962A (ko) * 2005-12-20 2008-08-20 노파르티스 아게 대사성 글루타메이트 수용체 조절제로서의 니코틴산 유도체
EP2272509A1 (en) * 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
US8703809B2 (en) * 2008-06-30 2014-04-22 Novartis Ag Combination products

Also Published As

Publication number Publication date
TN2010000155A1 (en) 2011-11-11
US20150272929A1 (en) 2015-10-01
WO2009047296A2 (en) 2009-04-16
RU2508107C2 (ru) 2014-02-27
IL204954A0 (en) 2010-11-30
RU2010118454A (ru) 2011-11-20
AU2008309621A1 (en) 2009-04-16
MA31798B1 (fr) 2010-10-01
NZ584856A (en) 2012-12-21
KR101572280B1 (ko) 2015-11-26
EP2211859B1 (en) 2016-01-06
CN101854935A (zh) 2010-10-06
WO2009047296A3 (en) 2009-08-20
CL2008003006A1 (es) 2009-05-08
BRPI0818560A2 (pt) 2019-09-24
US20100249136A1 (en) 2010-09-30
TW200924745A (en) 2009-06-16
JP2014240425A (ja) 2014-12-25
ZA201002423B (en) 2010-12-29
CA2701853A1 (en) 2009-04-16
EP2211859A2 (en) 2010-08-04
JP2011500529A (ja) 2011-01-06
SG185293A1 (en) 2012-11-29
KR20100088136A (ko) 2010-08-06
JP5743545B2 (ja) 2015-07-01

Similar Documents

Publication Publication Date Title
TN2010000155A1 (en) Organic compounds
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MY147247A (en) Organic compounds and their uses
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
MX2009002684A (es) Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico.
TNSN08496A1 (en) Aminothiazoles and their uses
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
MX2009009693A (es) Metodos para activar irs-1 y akt.
NL1030418A1 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
TN2009000495A1 (en) Macrocycles and their uses
MX2010004463A (es) Compuestos de indolina.
WO2009051661A3 (en) Substituted aryl alkylamino-oxy-analogs and uses thereof
WO2008085927A3 (en) Methods, compositions, and kits for the treatment of pain
WO2008103431A3 (en) Dnai - liposomes
WO2008008841A3 (en) Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders

Legal Events

Date Code Title Description
FG Grant or registration